|
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Clinical research trials and Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer. Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer clinical trial. Participants frequently obtain the most expert healthcare available for their Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer  Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
For Condition: Lymphoma,Multiple Myeloma,Leukemia
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Robert H. Lurie Cancer Center
Synopsis: RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of bone marrow and peripheral stem cell transplantation in treating patients who have hematologic cancer.
Details: OBJECTIVES: I. Determine the toxicity of unmanipulated bone marrow augmented with CD34+ enriched peripheral blood stem cells in patients with hematologic malignancies undergoing allogeneic transplantation. II. Evaluate this treatment regimen in terms of kinetics of hematopoietic engraftment, infection, severity of graft-vs-host disease, relapse rate, and cost effectiveness in this patient population. PROTOCOL OUTLINE: Patients undergo allogeneic transplantation comprising unmanipulated bone marrow with filgrastim (G-CSF)-mobilized, CD34+ enriched peripheral blood stem cells on day 0. Patients receive graft-vs-host disease prophylaxis comprising cyclosporine IV over 24 hours on day -1 and methylprednisolone IV or oral prednisone daily on days 7-65. Patients also receive G-CSF subcutaneously daily until blood counts recover. Patients are followed weekly for 3 months, at 6 months and 1 year, and then annually for 5 years. PROJECTED ACCRUAL: A total of 30-60 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 10 Years/65 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosed hematologic malignancy that is eligible for an active allogeneic bone marrow transplantation protocol and leukemia, lymphoma, myeloma, and aplastic anemia treatment protocols - HLA-identical or one antigen-mismatched related donor --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: 10 to 65 - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Other: No known sensitivity to E. coli derivatives
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RichardBurt, Study Chair, Robert H. Lurie Cancer Center
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611-3013
United States
Additional Information:
Study ID Numbers: CDR0000067474; NU-96H4,NCI-G99-1660
Study Start Date: October 1999
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004232
Other Leukemia Studies:
1. A Study of PS-341 Given to Patients With Multiple Myeloma who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
2. Safety and efficacy of single-agent CC-5013 in subjects with relapsed and refractory multiple myeloma
3. Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
4. Combined Bone Marrow and Kidney Transplant for Multiple Myeloma with Kidney Failure
5. Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Related Studies:
Other Leukemia Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
|
|
|
|
|
|
|
